The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Sulpiride: an Antipsychotic with Selective Dopaminergic Antagonist Properties
Abstract
Objective: To review the pharmacology, pharmacokinetics, clinical investigations, and adverse effects of sulpiride as a treatment for schizophrenia. Data Sources: Information was selected from a MEDLINE search of English-language medical literature using “sulpiride” as the search term. Manual searches of pertinent journal article bibliographies also were performed. Study Selection: Clinical investigations with a blind, controlled, randomized design and treatment durations of at least 6 weeks were preferred. Formal assessment of a patient's schizophrenia was required. One clinical investigation using a 4-week treatment duration and 1 open investigation were included for purposes of adverse reaction assessment. Data Extraction: Clinical investigations were evaluated for design, sample size, diagnosis, duration, and outcome. Data from all investigations were selected by 1 author and reviewed by both authors. Data Synthesis: Sulpiride is a substituted benzamide with selective dopaminergic blocking activity. Early pharmacology reports hypothesized that sulpiride was selective for dopamine (D)2 receptors only, but sulpiride also blocks D 3 and D 4 receptors. Sulpiride does not block D 1, adrenergic, cholinergic, gamma-aminobutyric acid–ergic, histaminergic, or serotonergic receptors to an appreciable extent. The oral bioavailability of sulpiride is poor, with estimates approximating 35%. Sulpiride does not appear to have an extensive first-pass metabolism, nor is it extensively protein-bound. There have been no identified active metabolites, and elimination appears to depend primarily on the kidneys. Clinical studies support sulpiride as being equally effective as active controls in the acute treatment of patients with schizophrenia. Daily doses permitted in these clinical investigations ranged from 100 to 3200 mg. Further investigation is required to determine the usefulness of sulpiride as a chronic treatment of schizophrenia and its effectiveness in treating the negative symptoms of schizophrenia. Sulpiride may cause extrapyramidal effects, autonomic effects, tardive dyskinesia, and the neuroleptic malignant syndrome. The incidence of these adverse reactions has not been established. Conclusions: Sulpiride is a safe and effective pharmacotherapeutic treatment for the acute management of schizophrenia. A unique pharmacology does not appear to provide sulpiride with a greater effectiveness than the standard antipsychotics, but may provide it with minor safety advantages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L., & Schwartz, J.-C. (1990) · Nature · doi:10.1038/347146a0 · Cited by 2,609
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
A COMPREHENSIVE PSYCHOPATHOLOGICAL RATING SCALE
Åsberg, M., Montgomery, S. A., Perris, C., Schalling, D., & Sedvall, G. (1978) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1978.tb02357.x · Cited by 1,326
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1
Sunahara, R. K., Guan, H.-C., O'Dowd, B. F., Seeman, P., Laurier, L. G., Ng, G., George, S. R., Torchia, J., Van Tol, H. H. M., & Niznik, H. B. (1991) · Nature · doi:10.1038/350614a0 · Cited by 1,165
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C., & Long, G. W. (1991) · JAMA · doi:10.1001/jama.1991.03460200114048 · Cited by 1,060
Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic Drugs
Farde, L. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800250087012 · Cited by 692
Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity
Pijnenburg, A. J. J., Honig, W. M. M., Van Der Heyden, J. A. M., & Van Rossum, J. M. (1976) · European Journal of Pharmacology · doi:10.1016/0014-2999(76)90299-5 · Cited by 566
Sokoloff, P., Andrieux, M., Besançon, R., Pilon, C., Martres, M.-P., Giros, B., & Schwartz, J.-C. (1992) · European Journal of Pharmacology: Molecular Pharmacology · doi:10.1016/0922-4106(92)90107-7 · Cited by 400
NOSIE-30: A Treatment-Sensitive Ward Behavior Scale
Honigfeld, G., Gillis, R. D., & Klett, C. J. (1966) · Psychological Reports · doi:10.2466/pr0.1966.19.1.180 · Cited by 353
Sokoloff, P., Martres, M. P., & Schwartz, J. C. (1980) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00499251 · Cited by 197
Ljungberg, T., & Ungerstedt, U. (1978) · Psychopharmacology · doi:10.1007/bf00432845 · Cited by 196
Sulpiride: A study of the effects on dopamine receptors in rat neostriatum and limbic forebrain
Trabucchi, M., Longoni, R., Fresia, P., & Spano, P. F. (1975) · Life Sciences · doi:10.1016/0024-3205(75)90176-9 · Cited by 192
The substituted benzamides - a novel class of dopamine antagonists
Jenner, P. G., & MARSDEN, C. D. (1979) · Life Sciences · doi:10.1016/0024-3205(79)90559-9 · Cited by 158
Vandereycken, W. (1984) · The British Journal of Psychiatry · doi:10.1192/bjp.144.3.288 · Cited by 149
Clinical Efficacy of Clozapine in Treatment-Refractory Schizophrenia: An Overview
Kane, J. M. (1992) · The British Journal of Psychiatry · doi:10.1192/s0007125000296918 · Cited by 147
Substituted benzamide drugs as selective neuroleptic agents.
Jenner, P. G., & MARSDEN, C. D. (1981) · PubMed · Cited by 122
SELECTIVE INCREASE OF BRAIN DOPAMINE SYNTHESIS BY SULPIRIDE
Tagliamonte, A., Montis, M. G. D., Olianas, M. C., Vargiu, L., Corsini, G. U., & Gessa, G. L. (1975) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1975.tb03852.x · Cited by 113
The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects
Wiesel, F. ‐., Alfredsson, G., Ehrnebo, M., & Sedvall, G. (1980) · European Journal of Clinical Pharmacology · doi:10.1007/bf00558453 · Cited by 107
PET Analysis Indicates Atypical Central Dopamine Receptor Occupancy in Clozapine-Treated Patients
Farde, L., & Nordström, A. (1992) · The British Journal of Psychiatry · doi:10.1192/s0007125000296888 · Cited by 106
Management of Gilles de la Tourette Syndrome Using Sulpiride
Robertson, M. M., Schnieden, V., & Lees, A. J. (1990) · Clinical Neuropharmacology · doi:10.1097/00002826-199006000-00005 · Cited by 91
A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia.
Quinn, N. P., & MARSDEN, C. D. (1984) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.47.8.844 · Cited by 84
Härnryd, C., Bjerkenstedt, L., Björk, K., Gullberg, B., Oxenstierna, G., Sedvall, G., Wiesel, F. ‐., Wik, G., & Åberg‐Wistedt, A. (1984) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1984.tb06856.x · Cited by 78
Alfredsson, G., H�rnryd, C., & Wiesel, F. ‐. (1985) · Psychopharmacology · doi:10.1007/bf00427315 · Cited by 71
Gerlach, J., Behnke, K., Heltberg, J., Munk‐Andersen, E., & Nielsen, H. (1985) · The British Journal of Psychiatry · doi:10.1192/bjp.147.3.283 · Cited by 71
Controlled Trial of Sulpiride in Chronic Schizophrenic Patients
Edwards, J. G., Alexander, J. R., Alexander, M. S., Gordon, A., & Zutchi, T. (1980) · The British Journal of Psychiatry · doi:10.1192/bjp.137.6.522 · Cited by 61
Anxiolytic potential of sulpiride, clozapine and derivatives in the open-field test
Bruhwyler, J., Chleide, E. M. G., Liégeois, J.-F., Delarge, J., & MERCIER, M. G. A. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90125-2 · Cited by 53
Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial.
Gb, C., Castrogiovanni, P., Conti, L., & Bonollo, L. (1975) · PubMed · Cited by 43
The evaluation of the anti-autistic activity of sulpiride.
Elizur, A., & Davidson, S. (1975) · PubMed · Cited by 34
Alfredsson, G., & Wiesel, F.-A. (1989) · Psychopharmacology · doi:10.1007/bf00445551 · Cited by 33
Systemic sulpiride increases dopamine metabolites in the lateral hypothalamus
Baptista, T., Hernandez, L., & Hoebel, B. G. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90325-c · Cited by 29
Use of Carbamazepine in Psychosis after Neuroleptic Malignant Syndrome
Peet, M., & Collier, J. (1990) · The British Journal of Psychiatry · doi:10.1192/bjp.156.4.579 · Cited by 29
Sulpiride‐induced tardive dystonia
Miller, L. G., & Jankovic, J. J. (1990) · Movement Disorders · doi:10.1002/mds.870050119 · Cited by 27
Sulpiride in tardive dyskinesia.
Schwartz, M., Moguillansky, L., Lanyi, G., & Sharf, B. (1990) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.53.9.800 · Cited by 20
Pharmacokinetics of Sulpiride in Humans after Intravenous and Intramuscular Administrations
Brès, J., & Bressolle, F. (1991) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600801206 · Cited by 18
CHRISTIE, J. E., Whalley, L. J., Hunter, R., et al. (1989) · Journal of Affective Disorders · doi:10.1016/0165-0327(89)90064-5 · Cited by 12
Ereshefsky, L., & Richards, A. L. (1992) · Palgrave Macmillan UK eBooks · doi:10.1007/978-1-349-13175-4_56 · Cited by 6
Cited by
Dopamine Modulates Adaptive Prediction Error Coding in the Human Midbrain and Striatum
Diederen, K. M. J., Ziauddeen, H., Vestergaard, M. D., Spencer, T., Schultz, W., & Fletcher, P. C. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1979-16.2016 · Cited by 110
Metadata
- Authors
- Caley, C. F., & Weber, S. S.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 1995-02
- Volume
- 29
- Issue
- 2
- Pages
- 152-160
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W184480178
- Cited by
- 264
- References
- 36
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.